Click here to view the slides referenced in the webcast.">

A Critical Assessment of Valve Performance and Outcomes in Patients at Low Risk for Surgery
See what leading interventionalists have to say about hot topics in TAVR today.

  • Patients Enrolled in the Evolut™ Low Risk Trial - the Critical Role of the Heart Team
    Gregory P. Fontana, Michael Deeb, and John Forrest
  • The Clinical Impact of Bioprosthetic Valve Performance After Surgery and TAVR
    Daniel O’Hair, Renuka Jain, and Hemal Gada
  • High-Level Results of the Evolut™ Low Risk Randomized Clinical Trial
    Daniel O’Hair, Michael Reardon, and John Forrest
  • Understanding Early and Late Mortality in Low Risk Randomized Trials
    Gregory P. Fontana, Michael Deeb, and Michael Reardon
  • Lifetime Management Considerations in Low Risk Patients
    Gregory P. Fontana, Renuka Jain, Hemal Gada, and Michael Deeb


 This program is supported by: Medtronic


Michael Deeb

Michael Deeb, MD
University of Michigan 
Ann Arbor, MI

Gregory Fontana Gregory P. Fontana, MD
Los Robles Hospital and Medical Center
Thousand Oaks, CA
Forrest, John
John Forrest, MD
Yale New Haven Hospital
New Haven, CT



Gada, Hemal.jpg

Hemal Gada, MD
Heart and Vascular
Institute UPMC Pinnacle
Harrisburg, PA

Renuka Jain Renuka Jain, MD
Aurora St. Luke's Medical Center
Milwaukee, WI
Daniel O'Hair
Daniel O'Hair, MD
Boulder Heart, Boulder Community Health
Boulder, CO



Michael Reardon

Michael Reardon, MD
Houston Methodist Debakey Heart & Vascular Center
Houston, TX



 This program is sponsored by: Medtronic